Bone marrow conventional karyotyping and fluorescence in situ hybridization: Defining an effective utilization strategy for evaluation of myelodysplastic syndromes

Rong He, Anne E. Wiktor, David K. Durnick, Paul J. Kurtin, Daniel L. Van Dyke, Ayalew Tefferi, Mrinal M Patnaik, Rhett P. Ketterling, Curtis A. Hanson

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objectives: The current standard of practice for evaluation of myelodysplastic syndromes (MDS) includes peripheral blood and bone marrow morphology review and conventional karyotyping. Karyotype provides a global view of the chromosome complement while fluorescence in situ hybridization (FISH) targets specific abnormalities. The aim of this study was to determine if an MDSFISH panel would add value beyond karyotype in MDS workup. Methods: We studied 505 patients who were evaluated for a possible MDS and had concurrent bone marrow examination, karyotyping, and MDS-FISH performed. Results: In total, 462 cases had adequate karyotyping (≥20 metaphases) and showed excellent concordance (96%, 445/462) between karyotyping and MDS-FISH. Additional FISH abnormalities had no impact on diagnosis and minimal impact on the cytogenetic prognostic scoring in the myeloid neoplasm cases (2%, 4/206). The concordance rate dropped to 82% (32/39) in the group with insufficient karyotyping (≥20 metaphases), and additional FISH findings in this subgroup had no impact on the diagnosis but altered the cytogenetic prognostic scoring in 10% (2/20) of myeloid neoplasm cases. Conclusions: In the evaluation of a possible MDS, FISH rarely provides additional value when karyotype is adequate. We propose a value-based, cost-effective algorithmic approach for conventional karyotyping and FISH testing in routine MDS workup.

Original languageEnglish (US)
Pages (from-to)86-94
Number of pages9
JournalAmerican Journal of Clinical Pathology
Volume146
Issue number1
DOIs
StatePublished - Jul 1 2016

Fingerprint

Karyotyping
Myelodysplastic Syndromes
Fluorescence In Situ Hybridization
Bone Marrow
Karyotype
Metaphase
Cytogenetics
Bone Marrow Examination
Neoplasms
Chromosomes
Costs and Cost Analysis

Keywords

  • Genetics
  • Hematology
  • Hematopathology
  • Molecular diagnostics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bone marrow conventional karyotyping and fluorescence in situ hybridization : Defining an effective utilization strategy for evaluation of myelodysplastic syndromes. / He, Rong; Wiktor, Anne E.; Durnick, David K.; Kurtin, Paul J.; Van Dyke, Daniel L.; Tefferi, Ayalew; Patnaik, Mrinal M; Ketterling, Rhett P.; Hanson, Curtis A.

In: American Journal of Clinical Pathology, Vol. 146, No. 1, 01.07.2016, p. 86-94.

Research output: Contribution to journalArticle

He, Rong ; Wiktor, Anne E. ; Durnick, David K. ; Kurtin, Paul J. ; Van Dyke, Daniel L. ; Tefferi, Ayalew ; Patnaik, Mrinal M ; Ketterling, Rhett P. ; Hanson, Curtis A. / Bone marrow conventional karyotyping and fluorescence in situ hybridization : Defining an effective utilization strategy for evaluation of myelodysplastic syndromes. In: American Journal of Clinical Pathology. 2016 ; Vol. 146, No. 1. pp. 86-94.
@article{ab0d0be83eb747e386e1e132830bc242,
title = "Bone marrow conventional karyotyping and fluorescence in situ hybridization: Defining an effective utilization strategy for evaluation of myelodysplastic syndromes",
abstract = "Objectives: The current standard of practice for evaluation of myelodysplastic syndromes (MDS) includes peripheral blood and bone marrow morphology review and conventional karyotyping. Karyotype provides a global view of the chromosome complement while fluorescence in situ hybridization (FISH) targets specific abnormalities. The aim of this study was to determine if an MDSFISH panel would add value beyond karyotype in MDS workup. Methods: We studied 505 patients who were evaluated for a possible MDS and had concurrent bone marrow examination, karyotyping, and MDS-FISH performed. Results: In total, 462 cases had adequate karyotyping (≥20 metaphases) and showed excellent concordance (96{\%}, 445/462) between karyotyping and MDS-FISH. Additional FISH abnormalities had no impact on diagnosis and minimal impact on the cytogenetic prognostic scoring in the myeloid neoplasm cases (2{\%}, 4/206). The concordance rate dropped to 82{\%} (32/39) in the group with insufficient karyotyping (≥20 metaphases), and additional FISH findings in this subgroup had no impact on the diagnosis but altered the cytogenetic prognostic scoring in 10{\%} (2/20) of myeloid neoplasm cases. Conclusions: In the evaluation of a possible MDS, FISH rarely provides additional value when karyotype is adequate. We propose a value-based, cost-effective algorithmic approach for conventional karyotyping and FISH testing in routine MDS workup.",
keywords = "Genetics, Hematology, Hematopathology, Molecular diagnostics",
author = "Rong He and Wiktor, {Anne E.} and Durnick, {David K.} and Kurtin, {Paul J.} and {Van Dyke}, {Daniel L.} and Ayalew Tefferi and Patnaik, {Mrinal M} and Ketterling, {Rhett P.} and Hanson, {Curtis A.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1093/ajcp/aqw077",
language = "English (US)",
volume = "146",
pages = "86--94",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "1",

}

TY - JOUR

T1 - Bone marrow conventional karyotyping and fluorescence in situ hybridization

T2 - Defining an effective utilization strategy for evaluation of myelodysplastic syndromes

AU - He, Rong

AU - Wiktor, Anne E.

AU - Durnick, David K.

AU - Kurtin, Paul J.

AU - Van Dyke, Daniel L.

AU - Tefferi, Ayalew

AU - Patnaik, Mrinal M

AU - Ketterling, Rhett P.

AU - Hanson, Curtis A.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Objectives: The current standard of practice for evaluation of myelodysplastic syndromes (MDS) includes peripheral blood and bone marrow morphology review and conventional karyotyping. Karyotype provides a global view of the chromosome complement while fluorescence in situ hybridization (FISH) targets specific abnormalities. The aim of this study was to determine if an MDSFISH panel would add value beyond karyotype in MDS workup. Methods: We studied 505 patients who were evaluated for a possible MDS and had concurrent bone marrow examination, karyotyping, and MDS-FISH performed. Results: In total, 462 cases had adequate karyotyping (≥20 metaphases) and showed excellent concordance (96%, 445/462) between karyotyping and MDS-FISH. Additional FISH abnormalities had no impact on diagnosis and minimal impact on the cytogenetic prognostic scoring in the myeloid neoplasm cases (2%, 4/206). The concordance rate dropped to 82% (32/39) in the group with insufficient karyotyping (≥20 metaphases), and additional FISH findings in this subgroup had no impact on the diagnosis but altered the cytogenetic prognostic scoring in 10% (2/20) of myeloid neoplasm cases. Conclusions: In the evaluation of a possible MDS, FISH rarely provides additional value when karyotype is adequate. We propose a value-based, cost-effective algorithmic approach for conventional karyotyping and FISH testing in routine MDS workup.

AB - Objectives: The current standard of practice for evaluation of myelodysplastic syndromes (MDS) includes peripheral blood and bone marrow morphology review and conventional karyotyping. Karyotype provides a global view of the chromosome complement while fluorescence in situ hybridization (FISH) targets specific abnormalities. The aim of this study was to determine if an MDSFISH panel would add value beyond karyotype in MDS workup. Methods: We studied 505 patients who were evaluated for a possible MDS and had concurrent bone marrow examination, karyotyping, and MDS-FISH performed. Results: In total, 462 cases had adequate karyotyping (≥20 metaphases) and showed excellent concordance (96%, 445/462) between karyotyping and MDS-FISH. Additional FISH abnormalities had no impact on diagnosis and minimal impact on the cytogenetic prognostic scoring in the myeloid neoplasm cases (2%, 4/206). The concordance rate dropped to 82% (32/39) in the group with insufficient karyotyping (≥20 metaphases), and additional FISH findings in this subgroup had no impact on the diagnosis but altered the cytogenetic prognostic scoring in 10% (2/20) of myeloid neoplasm cases. Conclusions: In the evaluation of a possible MDS, FISH rarely provides additional value when karyotype is adequate. We propose a value-based, cost-effective algorithmic approach for conventional karyotyping and FISH testing in routine MDS workup.

KW - Genetics

KW - Hematology

KW - Hematopathology

KW - Molecular diagnostics

UR - http://www.scopus.com/inward/record.url?scp=84982085211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982085211&partnerID=8YFLogxK

U2 - 10.1093/ajcp/aqw077

DO - 10.1093/ajcp/aqw077

M3 - Article

C2 - 27353768

AN - SCOPUS:84982085211

VL - 146

SP - 86

EP - 94

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 1

ER -